Today’s post is a review and fact check of stem cell supplements. What I found now in 2024 on stem cell pills and related supplements is concerning. As a stem cell biologist, I see risks here of both wasting one’s money and doing some harm. In certain cases, stem cell supplements are actually unapproved drugs […]
Fact-checking stem cell supplements in 2024 Read More »
Making a CRISPR baby is a controversial idea to even propose now for many reasons, yet even after He Jiankui’s train wreck some people have seemed eager to try it including apparently a scientist whose name perhaps many readers here are not so familiar with in this context: Professor Hui Yang. ‘CRISPR baby guys’ Is
Heads up on Hui Yang, another potential aspiring CRISPR baby researcher Read More »
Where do things stand today in 2020 with IPS cell research? It’s been 14 years since they were first reported, but they continue to make news. Back in 2006 I was wrapping up my postdoc with Bob Eisenman at The Hutch in Seattle, largely studying Myc, when Shinya Yamanaka published his first induced pluripotent stem
IPS cell field update: easy culture, Parkinson’s, scarring, immune cells, & mutations Read More »
When it comes to coverage of stem cell research in the media, science news can both be cool, but also surprising. Some of the more interesting publications don’t always draw news coverage too. This post is a list of recent notable pubs and news. First some pubs. How good are human brain organoids at modeling
Recommended reads: stem cell pubs plus science news Read More »
Here is my 2020 Stem Cell and Regenerative medicine Meetings List. Send me your listings if you don’t see your meeting here. Meeting listings are not endorsements and I try to make this list fairly comprehensive so it may even include some meetings that require a second look before deciding on attending. January Tissue Organoids
2020 Stem Cell & Regenerative Medicine Meetings Read More »
Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes
Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more Read More »
This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm
FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »
A new right-to-try company called Beacon of Hope is stirring some intense discussion. State and federal right-to-try laws could potentially change the fabric of how many investigational studies are conducted. That may happen through firms like Beacon of Hope. However, we don’t know much about the firm. I’m hoping to help change that. Today’s post
Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope Read More »
Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013
7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »
When people discuss “fat stem cells” they usually mean “stromal vascular fraction” or SVF. While references to fat or adipose stem cells can sometimes mean non-SVF materials, these days adipose SVF gets the most attention. But, does anyone have a clear picture of this biologic? Fortunately, it’s starting to come more into focus in recent years
What is stromal vascular fraction or SVF? Read More »